You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOuabain
Accession NumberDB01092  (APRD00135)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. [PubChem]
Structure
Thumb
Synonyms
3-(alpha-L-Rhamnopyranosyloxy)-1beta,5beta,11alpha,14,19-pentahydroxy-5beta-card-20(22)-enolide
G-Strophanthin
Ouabagenin L-Rhamnoside
Ouabagenin-L-rhamnosid
Ouabain
Ouabain anhydrous
Ouabaine
Oubain
Strodival
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
StrodivalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5ACL011P69
CAS number630-60-4
WeightAverage: 584.6525
Monoisotopic: 584.283276872
Chemical FormulaC29H44O12
InChI KeyLPMXVESGRSUGHW-HBYQJFLCSA-N
InChI
InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
IUPAC Name
4-[(1S,2R,3R,5S,7S,10R,11S,14R,15R,17R)-3,7,11,17-tetrahydroxy-2-(hydroxymethyl)-15-methyl-5-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
[H][C@@]12CC[C@]3(O)C[[email protected]](C[C@@H](O)[C@]3(CO)[C@@]1([H])[[email protected]](O)C[C@]1(C)[[email protected]](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[[email protected]](O)[C@@H](O)[[email protected]]1O
Pharmacology
IndicationFor the treatment of atrial fibrillation and flutter and heart failure
Structured Indications Not Available
PharmacodynamicsOuabain, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism of actionOuabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1Proteinyes
inhibitor
HumanP05023 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding60%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideOuabain may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolOuabain may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideOuabain may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidOuabain may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidOuabain may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineOuabain may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineOuabain may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineOuabain may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneOuabain may decrease the cardiotoxic activities of Abiraterone.Approved
ABT-263Ouabain may decrease the cardiotoxic activities of ABT-263.Investigational
AcebutololAcebutolol may increase the bradycardic activities of Ouabain.Approved
AclarubicinOuabain may decrease the cardiotoxic activities of Aclarubicin.Investigational
ActeosideOuabain may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibOuabain may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneOuabain may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptOuabain may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinOuabain may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleOuabain may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinOuabain may decrease the cardiotoxic activities of Aldesleukin.Approved
AlemtuzumabOuabain may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlfacalcidolAlfacalcidol may increase the arrhythmogenic activities of Ouabain.Approved, Nutraceutical
AlitretinoinOuabain may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineOuabain may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
AlprenololAlprenolol may increase the bradycardic activities of Ouabain.Approved, Withdrawn
AltretamineOuabain may decrease the cardiotoxic activities of Altretamine.Approved
Amg 386Ouabain may decrease the cardiotoxic activities of Amg 386.Investigational
AmikacinThe serum concentration of Ouabain can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Ouabain can be decreased when used in combination with Amiloride.Approved
AminocamptothecinOuabain may decrease the cardiotoxic activities of Aminocamptothecin.Investigational
AminoglutethimideOuabain may decrease the cardiotoxic activities of Aminoglutethimide.Approved
Aminolevulinic acidOuabain may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Ouabain can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Ouabain can be increased when it is combined with Amodiaquine.Approved
AmonafideOuabain may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.Approved, Investigational
AmrubicinOuabain may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineOuabain may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideOuabain may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleOuabain may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveOuabain may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinOuabain may decrease the cardiotoxic activities of annamycin.Investigational
Aop200704Aop200704 may increase the bradycardic activities of Ouabain.Investigational
AP 12009Ouabain may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Ouabain may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneOuabain may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Ouabain can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Ouabain can be decreased when it is combined with Arbekacin.Approved
ArotinololArotinolol may increase the bradycardic activities of Ouabain.Approved
Arsenic trioxideOuabain may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ASA404Ouabain may decrease the cardiotoxic activities of ASA404.Investigational
AsparaginaseOuabain may decrease the cardiotoxic activities of Asparaginase.Approved
AT-101Ouabain may decrease the cardiotoxic activities of AT-101.Investigational
AtenololAtenolol may increase the bradycardic activities of Ouabain.Approved
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Ouabain.Approved
AxitinibOuabain may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineOuabain may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineOuabain may decrease the cardiotoxic activities of Azathioprine.Approved
AZD2171Ouabain may decrease the cardiotoxic activities of AZD2171.Investigational
Azd4547Ouabain may decrease the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidOuabain may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Ouabain can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Ouabain can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatOuabain may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Ouabain.Experimental
BelinostatOuabain may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanOuabain may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineOuabain may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ouabain.Approved
BesifloxacinOuabain may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Ouabain.Approved
Betulinic AcidOuabain may decrease the cardiotoxic activities of Betulinic Acid.Investigational
BevacizumabOuabain may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Ouabain.Approved
BexaroteneOuabain may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
Bgj398Ouabain may decrease the cardiotoxic activities of Bgj398.Investigational
BicalutamideOuabain may decrease the cardiotoxic activities of Bicalutamide.Approved
BisoprololBisoprolol may increase the bradycardic activities of Ouabain.Approved
BizelesinOuabain may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinOuabain may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabOuabain may decrease the cardiotoxic activities of Blinatumomab.Approved
Bmn 673Ouabain may decrease the cardiotoxic activities of Bmn 673.Investigational
BopindololBopindolol may increase the bradycardic activities of Ouabain.Approved
BortezomibOuabain may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibOuabain may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinOuabain may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineOuabain may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Ouabain may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Ouabain may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Ouabain.Investigational
BufuralolBufuralol may increase the bradycardic activities of Ouabain.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ouabain.Approved
BupranololBupranolol may increase the bradycardic activities of Ouabain.Approved
BusulfanOuabain may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineOuabain may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelOuabain may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineOuabain may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibOuabain may decrease the cardiotoxic activities of Cabozantinib.Approved
CaiOuabain may decrease the cardiotoxic activities of Cai.Investigational
CalcidiolCalcidiol may increase the arrhythmogenic activities of Ouabain.Approved, Nutraceutical
CalcipotriolOuabain may decrease the cardiotoxic activities of Calcipotriol.Approved
CalcitriolCalcitriol may increase the arrhythmogenic activities of Ouabain.Approved, Nutraceutical
CalciumCalcium may increase the arrhythmogenic activities of Ouabain.Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Ouabain.Approved
Calcium carbonateCalcium carbonate may increase the arrhythmogenic activities of Ouabain.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Ouabain.Approved
Calcium citrateCalcium citrate may increase the arrhythmogenic activities of Ouabain.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Ouabain.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Ouabain.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Ouabain.Approved, Vet Approved
CamptothecinOuabain may decrease the cardiotoxic activities of Camptothecin.Experimental
CapecitabineOuabain may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Ouabain can be increased when it is combined with Carbimazole.Approved
CarbomycinThe serum concentration of Ouabain can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinOuabain may decrease the cardiotoxic activities of Carboplatin.Approved
CarfilzomibOuabain may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurOuabain may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineOuabain may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Ouabain.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Ouabain.Approved, Investigational
CatumaxomabOuabain may decrease the cardiotoxic activities of Catumaxomab.Investigational
CB1954Ouabain may decrease the cardiotoxic activities of CB1954.Experimental
CediranibOuabain may decrease the cardiotoxic activities of Cediranib.Investigational
CelecoxibOuabain may decrease the cardiotoxic activities of Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the bradycardic activities of Ouabain.Approved, Investigational
CeritinibOuabain may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabOuabain may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilOuabain may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Ouabain can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain.Approved, Vet Approved
ChlorotrianiseneOuabain may decrease the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ouabain.Approved
CholecalciferolCholecalciferol may increase the arrhythmogenic activities of Ouabain.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinOuabain may decrease the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinOuabain may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Ouabain.Approved
CisplatinOuabain may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineOuabain may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Ouabain can be increased when it is combined with Clarithromycin.Approved
ClofarabineOuabain may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
clorarabineOuabain may decrease the cardiotoxic activities of clorarabine.Investigational
ColchicineOuabain may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CordycepinOuabain may decrease the cardiotoxic activities of Cordycepin.Investigational
CrenolanibOuabain may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibOuabain may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminOuabain may decrease the cardiotoxic activities of Curcumin.Investigational
CyclophosphamideOuabain may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateOuabain may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineOuabain may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibOuabain may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineOuabain may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinOuabain may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabOuabain may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibOuabain may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinOuabain may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Ouabain.Approved
DecitabineOuabain may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
Denileukin diftitoxOuabain may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinOuabain may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneOuabain may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneOuabain may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DienogestOuabain may decrease the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolOuabain may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DihydrostreptomycinThe serum concentration of Ouabain can be decreased when it is combined with Dihydrostreptomycin.Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Ouabain.Approved
DiindolylmethaneOuabain may decrease the cardiotoxic activities of Diindolylmethane.Investigational
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
DinutuximabOuabain may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelOuabain may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Ouabain.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Ouabain.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Ouabain.Approved
DoxifluridineOuabain may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinOuabain may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
EcabetOuabain may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
efaproxiralOuabain may decrease the cardiotoxic activities of efaproxiral.Investigational
EflornithineOuabain may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Ouabain may decrease the cardiotoxic activities of EG009.Investigational
ElsamitrucinOuabain may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EltrombopagThe serum concentration of Ouabain can be increased when it is combined with Eltrombopag.Approved
EndostatinOuabain may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinOuabain may decrease the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinOuabain may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatOuabain may decrease the cardiotoxic activities of Entinostat.Investigational
EpirubicinOuabain may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Ouabain can be decreased when used in combination with Eplerenone.Approved
EpofolateOuabain may decrease the cardiotoxic activities of Epofolate.Investigational
Epothilone BOuabain may decrease the cardiotoxic activities of Epothilone B.Experimental, Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Ouabain.Approved, Nutraceutical
EribulinOuabain may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibOuabain may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Ouabain can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Ouabain.Approved
EstramustineOuabain may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.Approved
EtanidazoleOuabain may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilOuabain may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateOuabain may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoposideOuabain may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusOuabain may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanOuabain may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneOuabain may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindOuabain may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideOuabain may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineOuabain may decrease the cardiotoxic activities of Fiacitabine.Investigational
FlavopiridolOuabain may decrease the cardiotoxic activities of Flavopiridol.Experimental, Investigational
FleroxacinOuabain may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineOuabain may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineOuabain may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineOuabain may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilOuabain may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideOuabain may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneOuabain may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinOuabain may decrease the cardiotoxic activities of Formycin.Experimental
FotemustineOuabain may decrease the cardiotoxic activities of Fotemustine.Experimental
FramycetinThe serum concentration of Ouabain can be decreased when it is combined with Framycetin.Approved
FulvestrantOuabain may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinOuabain may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Ouabain.Approved, Vet Approved
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Ouabain.Approved
Gallium nitrateOuabain may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinOuabain may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinOuabain may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibOuabain may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinOuabain may decrease the cardiotoxic activities of Geldanamycin.Experimental
GemcitabineOuabain may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinOuabain may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinOuabain may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GeneticinThe serum concentration of Ouabain can be decreased when it is combined with Geneticin.Experimental
GenisteinOuabain may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Ouabain can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Ouabain can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside COuabain may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinOuabain may decrease the cardiotoxic activities of Goserelin.Approved
GrepafloxacinOuabain may decrease the cardiotoxic activities of Grepafloxacin.Withdrawn
GusperimusOuabain may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinOuabain may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneOuabain may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolOuabain may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ouabain.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ouabain.Approved
HydroxychloroquineThe serum concentration of Ouabain can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateOuabain may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaOuabain may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Ouabain can be decreased when it is combined with Hygromycin B.Vet Approved
IbrutinibOuabain may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinOuabain may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibOuabain may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideOuabain may decrease the cardiotoxic activities of Ifosfamide.Approved
Il 4Ouabain may decrease the cardiotoxic activities of Il 4.Investigational
ImatinibOuabain may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodOuabain may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Ouabain.Approved
IndenololIndenolol may increase the bradycardic activities of Ouabain.Withdrawn
IndirubinOuabain may decrease the cardiotoxic activities of Indirubin.Investigational
INNO-206The serum concentration of Ouabain can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aOuabain may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bOuabain may decrease the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneOuabain may decrease the cardiotoxic activities of Iobenguane.Approved
IpilimumabOuabain may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanOuabain may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenOuabain may decrease the cardiotoxic activities of Irofulven.Investigational
ItraconazoleThe serum concentration of Ouabain can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneOuabain may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibOuabain may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Ouabain can be increased when it is combined with Josamycin.Approved
KanamycinThe serum concentration of Ouabain can be decreased when it is combined with Kanamycin.Approved, Vet Approved
KaolinThe serum concentration of Ouabain can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Ouabain can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Ouabain may decrease the cardiotoxic activities of KOS-1584.Investigational
L-alanosineOuabain may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Ouabain.Approved
LanreotideOuabain may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibOuabain may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LeflunomideOuabain may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideOuabain may decrease the cardiotoxic activities of Lenalidomide.Approved
LenvatinibOuabain may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleOuabain may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideOuabain may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Ouabain.Approved
LevofloxacinOuabain may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleOuabain may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Ouabain.Approved
LomefloxacinOuabain may decrease the cardiotoxic activities of Lomefloxacin.Approved
LomustineOuabain may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineOuabain may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
Ly2801653Ouabain may decrease the cardiotoxic activities of Ly2801653.Investigational
LycopeneOuabain may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideOuabain may decrease the cardiotoxic activities of Mafosfamide.Investigational
MasitinibOuabain may decrease the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolOuabain may decrease the cardiotoxic activities of Masoprocol.Approved
MaxacalcitolOuabain may decrease the cardiotoxic activities of Maxacalcitol.Approved
MDX-1106Ouabain may decrease the cardiotoxic activities of MDX-1106.Investigational
MebendazoleOuabain may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineOuabain may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneOuabain may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateOuabain may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateOuabain may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanOuabain may decrease the cardiotoxic activities of Melphalan.Approved
MequinolOuabain may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineOuabain may decrease the cardiotoxic activities of Mercaptopurine.Approved
MesalazineThe serum concentration of Ouabain can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Ouabain can be increased when it is combined with Methimazole.Approved
MethotrexateOuabain may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ouabain.Approved
Methyl aminolevulinateOuabain may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneOuabain may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneOuabain may decrease the cardiotoxic activities of Methyltestosterone.Approved
MetipranololMetipranolol may increase the bradycardic activities of Ouabain.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Ouabain.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Ouabain.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain.Approved
MetoprololMetoprolol may increase the bradycardic activities of Ouabain.Approved, Investigational
MetrizamideThe serum concentration of Ouabain can be decreased when it is combined with Metrizamide.Approved
MGI-114Ouabain may decrease the cardiotoxic activities of MGI-114.Investigational
MidodrineOuabain may increase the bradycardic activities of Midodrine.Approved
MidostaurinOuabain may decrease the cardiotoxic activities of Midostaurin.Investigational
MiltefosineOuabain may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleOuabain may decrease the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneOuabain may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolOuabain may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinOuabain may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneOuabain may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneOuabain may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Ouabain.Approved
MizoribineOuabain may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Ouabain may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimOuabain may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumOuabain may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinOuabain may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidOuabain may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadololNadolol may increase the bradycardic activities of Ouabain.Approved
Nalidixic AcidOuabain may decrease the cardiotoxic activities of Nalidixic Acid.Approved
NamitecanOuabain may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxOuabain may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Ouabain can be decreased when it is combined with Neamine.Experimental
NecitumumabOuabain may decrease the cardiotoxic activities of Necitumumab.Approved
NelarabineOuabain may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Ouabain can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Ouabain.Investigational
NetilmicinThe serum concentration of Ouabain can be decreased when it is combined with Netilmicin.Approved
NiguldipineOuabain may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibOuabain may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideOuabain may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineOuabain may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibOuabain may decrease the cardiotoxic activities of Nintedanib.Approved
NivolumabOuabain may decrease the cardiotoxic activities of Nivolumab.Approved
Nk012Ouabain may decrease the cardiotoxic activities of Nk012.Investigational
nocodazoleOuabain may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedOuabain may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinOuabain may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabOuabain may decrease the cardiotoxic activities of Obinutuzumab.Approved
OctreotideOuabain may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabOuabain may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinOuabain may decrease the cardiotoxic activities of Ofloxacin.Approved
OlaparibOuabain may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Ouabain can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Ouabain can be decreased when it is combined with Olsalazine.Approved
Omacetaxine mepesuccinateOuabain may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OprelvekinOuabain may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibOuabain may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinOuabain may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
OxprenololOxprenolol may increase the bradycardic activities of Ouabain.Approved
PaclitaxelOuabain may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibOuabain may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideOuabain may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateOuabain may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Ouabain.Approved
PanitumumabOuabain may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatOuabain may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Ouabain.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Ouabain.Approved, Investigational
ParomomycinThe serum concentration of Ouabain can be decreased when it is combined with Paromomycin.Approved, Investigational
PARP inhibitorOuabain may decrease the cardiotoxic activities of PARP inhibitor.Investigational
PazopanibOuabain may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinOuabain may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinOuabain may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseOuabain may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabOuabain may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedOuabain may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Ouabain.Approved, Investigational
PenclomedineOuabain may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinOuabain may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabOuabain may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenylacetic acidOuabain may decrease the cardiotoxic activities of Phenylacetic acid.Approved
PindololPindolol may increase the bradycardic activities of Ouabain.Approved
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Ouabain.Approved
PipobromanOuabain may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinOuabain may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Ouabain.Experimental
PirfenidoneOuabain may decrease the cardiotoxic activities of Pirfenidone.Investigational
PirlindoleOuabain may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneOuabain may decrease the cardiotoxic activities of Pixantrone.Investigational
PlevitrexedOuabain may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinOuabain may decrease the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxOuabain may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinOuabain may decrease the cardiotoxic activities of Podophyllin.Approved
polyacrylic acidOuabain may decrease the cardiotoxic activities of polyacrylic acid.Investigational
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Ouabain.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Ouabain.Approved
PomalidomideOuabain may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibOuabain may decrease the cardiotoxic activities of Ponatinib.Approved
PorfimerOuabain may decrease the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinOuabain may decrease the cardiotoxic activities of porfiromycin.Investigational
PractololPractolol may increase the bradycardic activities of Ouabain.Approved
PralatrexateOuabain may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineOuabain may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneOuabain may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneOuabain may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Ouabain can be increased when it is combined with Primaquine.Approved
ProcarbazineOuabain may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Ouabain can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Ouabain.Approved, Investigational
PropylthiouracilThe serum concentration of Ouabain can be increased when it is combined with Propylthiouracil.Approved
Purine RibosideOuabain may decrease the cardiotoxic activities of Purine Riboside.Experimental
PuromycinOuabain may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Ouabain.Approved, Vet Approved
PyrazoloacridineOuabain may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
Qlt091001Ouabain may decrease the cardiotoxic activities of Qlt091001.Investigational
QuinacrineOuabain may decrease the cardiotoxic activities of Quinacrine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Ouabain.Approved
QuinidineThe serum concentration of Ouabain can be increased when it is combined with Quinidine.Approved
Radium Ra 223 DichlorideOuabain may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedOuabain may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabOuabain may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabOuabain may decrease the cardiotoxic activities of Ranibizumab.Approved
RanpirnaseOuabain may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Ouabain.Withdrawn
RegorafenibOuabain may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ouabain.Approved
ResveratrolOuabain may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Rhodamine 6GOuabain may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Ouabain can be decreased when it is combined with Ribostamycin.Approved
RituximabOuabain may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Ouabain.Approved
RomidepsinOuabain may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimOuabain may decrease the cardiotoxic activities of Romiplostim.Approved
RoquinimexOuabain may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanOuabain may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibOuabain may decrease the cardiotoxic activities of Rucaparib.Investigational
RuxolitinibOuabain may decrease the cardiotoxic activities of Ruxolitinib.Approved
SalirasibOuabain may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibOuabain may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinOuabain may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibOuabain may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibOuabain may decrease the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolOuabain may decrease the cardiotoxic activities of Seocalcitol.Experimental
SiltuximabOuabain may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusOuabain may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Ouabain can be decreased when it is combined with Sisomicin.Investigational
Sodium phenylbutyrateOuabain may decrease the cardiotoxic activities of Sodium phenylbutyrate.Approved
SolithromycinThe serum concentration of Ouabain can be increased when it is combined with Solithromycin.Investigational
SonidegibOuabain may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SonifilanOuabain may decrease the cardiotoxic activities of Sonifilan.Investigational
SorafenibOuabain may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Ouabain.Approved
SP1049CThe serum concentration of Ouabain can be decreased when it is combined with SP1049C.Investigational
SparfloxacinOuabain may decrease the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidOuabain may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinOuabain may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Ouabain can be decreased when it is combined with Spectinomycin.Approved, Vet Approved
SpiramycinThe serum concentration of Ouabain can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Ouabain can be decreased when used in combination with Spironolactone.Approved
squalamineOuabain may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Ouabain may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Ouabain can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinOuabain may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Ouabain.Approved
SulfasalazineThe serum concentration of Ouabain can be decreased when it is combined with Sulfasalazine.Approved
SulforaphaneOuabain may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacOuabain may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ouabain.Approved
SunitinibOuabain may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminOuabain may decrease the cardiotoxic activities of Suramin.Approved
SwainsonineOuabain may decrease the cardiotoxic activities of Swainsonine.Experimental
TalaporfinOuabain may decrease the cardiotoxic activities of Talaporfin.Investigational
TamoxifenOuabain may decrease the cardiotoxic activities of Tamoxifen.Approved
TegafurOuabain may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Ouabain can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Ouabain can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinOuabain may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinOuabain may decrease the cardiotoxic activities of Temoporfin.Approved
TemozolomideOuabain may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusOuabain may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideOuabain may decrease the cardiotoxic activities of Teniposide.Approved
TeriflunomideThe serum concentration of Ouabain can be increased when it is combined with Teriflunomide.Approved
TestolactoneOuabain may decrease the cardiotoxic activities of Testolactone.Approved
TetrathiomolybdateOuabain may decrease the cardiotoxic activities of Tetrathiomolybdate.Investigational
TezacitabineOuabain may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideOuabain may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaOuabain may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinOuabain may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiboloneOuabain may decrease the cardiotoxic activities of Tibolone.Approved
TimololTimolol may increase the bradycardic activities of Ouabain.Approved
TioguanineOuabain may decrease the cardiotoxic activities of Tioguanine.Approved
TipifarnibOuabain may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineOuabain may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibOuabain may decrease the cardiotoxic activities of Tivozanib.Investigational
Tnp 470Ouabain may decrease the cardiotoxic activities of Tnp 470.Investigational
TobramycinThe serum concentration of Ouabain can be decreased when it is combined with Tobramycin.Approved, Investigational
TopotecanOuabain may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain.Approved
ToremifeneOuabain may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabOuabain may decrease the cardiotoxic activities of Tositumomab.Approved
TrabectedinOuabain may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibOuabain may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabOuabain may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineOuabain may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TreosulfanOuabain may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarOuabain may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinOuabain may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Ouabain can be decreased when used in combination with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Ouabain.Approved, Vet Approved
TrifluridineOuabain may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneOuabain may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateOuabain may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptorelinOuabain may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideOuabain may decrease the cardiotoxic activities of Trofosfamide.Investigational
TroleandomycinThe serum concentration of Ouabain can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinOuabain may decrease the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineOuabain may decrease the cardiotoxic activities of Troxacitabine.Investigational
TTNPBOuabain may decrease the cardiotoxic activities of TTNPB.Experimental
TubercidinOuabain may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Ouabain.Approved
TylosinThe serum concentration of Ouabain can be increased when it is combined with Tylosin.Vet Approved
UbenimexOuabain may decrease the cardiotoxic activities of Ubenimex.Experimental
Uracil mustardOuabain may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanOuabain may decrease the cardiotoxic activities of Vadimezan.Investigational
Val 083Ouabain may decrease the cardiotoxic activities of Val 083.Investigational
ValrubicinOuabain may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibOuabain may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideOuabain may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Ouabain.Approved
VeliparibOuabain may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibOuabain may decrease the cardiotoxic activities of Vemurafenib.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
VerteporfinOuabain may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneOuabain may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineOuabain may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineOuabain may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineOuabain may decrease the cardiotoxic activities of Vindesine.Approved
VinflunineOuabain may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineOuabain may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideOuabain may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibOuabain may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin AOuabain may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatOuabain may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
ZorubicinOuabain may decrease the cardiotoxic activities of Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gao J, Wymore RS, Wang Y, Gaudette GR, Krukenkamp IB, Cohen IS, Mathias RT: Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides. J Gen Physiol. 2002 Apr;119(4):297-312. [PubMed:11929882 ]
  2. Saunders R, Scheiner-Bobis G: Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. Eur J Biochem. 2004 Mar;271(5):1054-62. [PubMed:15009217 ]
  3. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63. [PubMed:1648735 ]
  4. Hamlyn JM, Laredo J, Shah JR, Lu ZR, Hamilton BP: 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann N Y Acad Sci. 2003 Apr;986:685-93. [PubMed:12763919 ]
  5. Laredo J, Hamilton BP, Hamlyn JM: Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994 Aug;135(2):794-7. [PubMed:8033829 ]
External Links
ATC CodesC01AC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9064
Blood Brain Barrier-0.5562
Caco-2 permeable-0.9052
P-glycoprotein substrateSubstrate0.8773
P-glycoprotein inhibitor INon-inhibitor0.5313
P-glycoprotein inhibitor IINon-inhibitor0.6281
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.8563
CYP450 2D6 substrateNon-substrate0.8844
CYP450 3A4 substrateSubstrate0.685
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9242
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9271
CYP450 3A4 inhibitorNon-inhibitor0.9241
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9179
Ames testNon AMES toxic0.9172
CarcinogenicityNon-carcinogens0.9638
BiodegradationNot ready biodegradable0.9784
Rat acute toxicity4.7797 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9551
hERG inhibition (predictor II)Inhibitor0.8457
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point200 °CPhysProp
water solubility1.03E+004 mg/LNot Available
logP-2.00SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility4.61 mg/mLALOGPS
logP-1ALOGPS
logP-2.8ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)7.18ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area206.6 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity140.83 m3·mol-1ChemAxon
Polarizability59.93 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • 19-hydroxysteroid
  • 11-hydroxysteroid
  • 11-alpha-hydroxysteroid
  • Hydroxysteroid
  • 5-hydroxysteroid
  • O-glycosyl compound
  • Glycosyl compound
  • Oxane
  • Monosaccharide
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Mentre P, Debey P: An unexpected effect of an ouabain-sensitive ATPase activity on the amount of antigen-antibody complexes formed in situ. Cell Mol Biol (Noisy-le-grand). 1999 Sep;45(6):781-91. [PubMed:10541475 ]
  2. Qazzaz HM, El-Masri MA, Stolowich NJ, Valdes R Jr: Two biologically active isomers of dihydroouabain isolated from a commercial preparation. Biochim Biophys Acta. 1999 Nov 16;1472(3):486-97. [PubMed:10564763 ]
  3. Tao QF, Hollenberg NK, Graves SW: Sodium pump inhibition and regional expression of sodium pump alpha-isoforms in lens. Hypertension. 1999 Nov;34(5):1168-74. [PubMed:10567200 ]
  4. Hawke TJ, Willmets RG, Lindinger MI: K+ transport in resting rat hind-limb skeletal muscle in response to paraxanthine, a caffeine metabolite. Can J Physiol Pharmacol. 1999 Nov;77(11):835-43. [PubMed:10593655 ]
  5. Almotrefi AA, Basco C, Moorji A, Dzimiri N: Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+ -K+ ATPase. Can J Physiol Pharmacol. 1999 Nov;77(11):866-70. [PubMed:10593659 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Li L, Lee TK, Meier PJ, Ballatori N: Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem. 1998 Jun 26;273(26):16184-91. [PubMed:9632674 ]
  2. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
  3. Bossuyt X, Muller M, Meier PJ: Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol. 1996 Nov;25(5):733-8. [PubMed:8938553 ]
  4. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646 ]
  5. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
  6. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, Hagenbuch B: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol. 1999 Apr;276(4 Pt 1):G1037-42. [PubMed:10198348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first...
Gene Name:
SLCO4C1
Uniprot ID:
Q6ZQN7
Molecular Weight:
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, Hagenbuch B: Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta. 2002 Aug 19;1564(1):183-8. [PubMed:12101011 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23